Milenia Labs has agreed to distribute Cynvenio Biosystems' ClearID Breast Cancer test in Mexico.
It is the first blood test for treatment selection and monitoring of patients with advanced breast cancer.
With the distribution agreement, ClearID system will be available exclusively at Milenia Labs’ 12 diagnostic centres in Mexico.
The test has been designed for patients undergoing breast cancer treatment and those who require follow-up testing at regular intervals after the therapy’s completion.
It uses molecular analysis to quickly and precisely generate real-time information on the activities of cancer cells. The test uses normal blood draw to detect the presence of scarce populations of cancer cells in the bloodstream and identifies gene alterations that can signal resistance to therapy.
Milenia will also offer Cynvenio’s PD-L1 gene expression reflex assay and other Cynvenio assays as they become commercially available.
ClearID Breast Cancer is based on Cynvenio’s LiquidBiopsy approach for tumour monitoring. The test analyses a combination of DNA from circulating tumour cells (CTC), cell-free DNA (cfDNA) and germline DNA (gDNA).
Milenia Labs’ director general Salvador Cardona said: “Liquid biopsy is revolutionizing the treatment of cancer in Mexico because it offers a better understanding of the genetic basis of cancer and is a non-invasive, personalized medicine tool that is very convenient and practical for the patient.
“Our mission is to provide the Mexican market with the highest quality and most innovative diagnostic tests from international providers.
“Cynvenio’s ClearID Breast Cancer test provides an excellent new option for patients based on state of the art liquid biopsy technology that has the benefit of being more affordable compared to other tests in this category.”
Cynvenio Clinical Diagnostics chief commercial officer Humberto Huerta said: “Milenia Labs has a successful track record of innovation in Mexico and an enviable network of partner labs throughout the country. This agreement is the cornerstone of our plan to broaden access to ClearID Breast testing services outside the United States.”